TG THERAPEUTICS, INC. 8-K

What Happened
TG Therapeutics, Inc. filed a Form 8-K on June 3, 2026 reporting positive pharmacokinetic (PK), pharmacodynamic (PD), safety and tolerability results from its Phase 1 clinical trial of a subcutaneous formulation of ublituximab (the active agent in BRIUMVI) in patients with relapsing forms of multiple sclerosis (RMS). The company issued a press release with these results, which is attached as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: June 3, 2026 (Form 8-K, Item 8.01; press release attached as Exhibit 99.1).
• Trial stage: Phase 1 clinical trial evaluating a subcutaneous (SC) formulation of ublituximab.
• Reported outcomes: Positive PK and PD results and favorable safety and tolerability in RMS patients (as stated in the press release).
• Drug: ublituximab — active agent in marketed product BRIUMVI (company is exploring an SC formulation).

Why It Matters
Positive Phase 1 PK/PD and safety data are an early clinical milestone that can support further development of a subcutaneous formulation. For investors, this update is relevant to TG Therapeutics’ pipeline progress and the potential expansion of ublituximab’s delivery options, which may affect future clinical plans and commercial strategy. The filing does not provide detailed efficacy or regulatory outcomes; it documents initial tolerability and pharmacologic profile that the company can use to inform next steps.